Pear Therapeutics, Inc. (NASDAQ:PEAR – Get Rating) saw a significant decrease in short interest during the month of May. As of May 31st, there was short interest totalling 1,150,000 shares, a decrease of 19.6% from the May 15th total of 1,430,000 shares. Based on an average daily volume of 319,800 shares, the days-to-cover ratio is […]
Pear Therapeutics (NASDAQ:PEAR – Get Rating)‘s stock had its “buy” rating reiterated by Chardan Capital in a report released on Monday, PriceTargets.com reports. Separately, Citigroup raised their target price on shares of Pear Therapeutics from $10.00 to $11.00 and gave the stock a “buy” rating in a report on Tuesday, May 17th. One equities research […]
Pear Therapeutics (NASDAQ:PEAR – Get Rating) and Better Therapeutics (NASDAQ:BTTX – Get Rating) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, dividends, earnings, risk, analyst recommendations, valuation and profitability. Profitability This table compares Pear Therapeutics and Better Therapeutics’ […]
Sema4 (NASDAQ:SMFR – Get Rating) and Pear Therapeutics (NASDAQ:PEAR – Get Rating) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, dividends, earnings and risk. Valuation & Earnings This table compares Sema4 and Pear Therapeutics’ […]
Pear Therapeutics (NASDAQ:PEAR – Get Rating) and Covalon Technologies (OTCMKTS:CVALF – Get Rating) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, valuation, dividends, earnings and risk. Analyst Recommendations This is a summary of recent ratings […]